Cysteine Proteases in MHC Class II Antigen Presentation
MHC II 类抗原呈递中的半胱氨酸蛋白酶
基本信息
- 批准号:6580160
- 负责人:
- 金额:$ 33.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1993
- 资助国家:美国
- 起止时间:1993-01-01 至 2007-12-31
- 项目状态:已结题
- 来源:
- 关键词:MHC class II antigen T lymphocyte active sites antigen presentation asthma autoimmunity cellular immunity cellular polarity clinical research cysteine endopeptidases dendritic cells enzyme activity flow cytometry gene targeting genetically modified animals human subject immunoglobulin E immunoregulation laboratory mouse lung disorder mast cell molecular chaperones protease inhibitor site directed mutagenesis tissue /cell culture
项目摘要
DESCRIPTION: (provided by applicant): The endosomal cysteine protease, cathepsin S, has a key role in MHC class II (MHCII)-dependent immunity through its role in degradation of the MHCII-associated chaperone, the invariant chain (Ii). But studies of cathepsin S -/- mice also reveal unexpected findings. Cathepsin S deficiency predominantly affects Thl dependent immunity. IgE responses and Th2-driven pulmonary inflammation, while dependent on cysteine proteases, are normal or increased in cathepsin S -/- mice. Indeed baseline IgE levels and lung mRNA of proinflammatory cytokines in these mice are elevated. Surprisingly, high IgE levels and cytokines are mast cell-dependent. These observations imply additional proteases, and perhaps additional antigen presenting cells (APC), are important to MHCII function and that protease dysregulation can skew, not just block, MHCII-dependent immune responses. Experiments are directed toward understanding how proteases can effect polarization of T and B cell development relevant to lung disease. Mechanisms of peptide loading in cathepsin S-deficient APC will be defined. Mice deficient in the Ii-degrading APC protease cathepsin F have been recently generated and will be used to test the hypothesis that cathepsin F rescues MHC class II peptide display in myeloid APCs, thereby favoring Th2 polarization. Selective protease inhibitors will be used to determine if a set of protease activities in human APC are required for Th2 cytokine production by allergen stimulated T cells. The mechanisms by which mast cells promote APC-dependent IgE production will be explored by reconstitution of mast cell deficient mice (Wsh) with mast cells cultured from S-/- or cytokine deficient mice. The overall goal of this application is to understand the molecular basis for protease dependent polarization of T cell and B cell immune responses and to learn how to exploit this process to ameliorate CD4+ T cell driven disorders such as autoimmunity and asthma.
产品说明:(申请人提供):内体半胱氨酸蛋白酶,组织蛋白酶S,通过其在MHCII相关的伴侣蛋白,不变链(Ii)的降解中的作用,在MHCII类(MHCII)依赖性免疫中具有关键作用。但是对组织蛋白酶S -/-小鼠的研究也揭示了意想不到的发现。组织蛋白酶S缺乏主要影响Thl依赖性免疫。IgE应答和Th 2驱动的肺部炎症,虽然依赖于半胱氨酸蛋白酶,但在组织蛋白酶S -/-小鼠中是正常的或增加的。事实上,这些小鼠中的基线IgE水平和促炎细胞因子的肺mRNA升高。令人惊讶的是,高IgE水平和细胞因子是肥大细胞依赖性的。这些观察结果意味着额外的蛋白酶,也许还有额外的抗原呈递细胞(APC),对MHCII功能很重要,并且蛋白酶失调可以扭曲,而不仅仅是阻断MHCII依赖性免疫应答。实验旨在了解蛋白酶如何影响与肺部疾病相关的T和B细胞发育的极化。将定义在组织蛋白酶S缺陷型APC中肽加载的机制。最近已经产生了II-降解APC蛋白酶组织蛋白酶F缺陷的小鼠,并将其用于测试组织蛋白酶F拯救髓样APC中的MHC II类肽展示,从而有利于Th 2极化的假设。选择性蛋白酶抑制剂将用于确定人APC中的一组蛋白酶活性是否是过敏原刺激的T细胞产生Th 2细胞因子所需的。肥大细胞促进APC依赖性IgE产生的机制将通过用从S-/-或细胞因子缺陷小鼠培养的肥大细胞重建肥大细胞缺陷小鼠(Wsh)来探索。本申请的总体目标是了解T细胞和B细胞免疫应答的蛋白酶依赖性极化的分子基础,并了解如何利用该过程来改善CD 4 + T细胞驱动的疾病,例如自身免疫和哮喘。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Harold A Chapman其他文献
Harold A Chapman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Harold A Chapman', 18)}}的其他基金
Phase 1 study of oral epigallocatechin-3-gallate (EGCG) in IPF patients
IPF 患者口服表没食子儿茶素-3-没食子酸酯 (EGCG) 的 1 期研究
- 批准号:
10702133 - 财政年份:2022
- 资助金额:
$ 33.96万 - 项目类别:
Phase 1 study of oral epigallocatechin-3-gallate (EGCG) in IPF patients
IPF 患者口服表没食子儿茶素-3-没食子酸酯 (EGCG) 的 1 期研究
- 批准号:
10418169 - 财政年份:2022
- 资助金额:
$ 33.96万 - 项目类别:
Program to promote lung regeneration and block fibrosis
促进肺再生和阻止纤维化的计划
- 批准号:
9893639 - 财政年份:2020
- 资助金额:
$ 33.96万 - 项目类别:
Program to promote lung regeneration and block fibrosis
促进肺再生和阻止纤维化的计划
- 批准号:
10570862 - 财政年份:2020
- 资助金额:
$ 33.96万 - 项目类别:
Epithelial stem/progenitor cells as repair agents in diffuse alveolar damage
上皮干/祖细胞作为弥漫性肺泡损伤的修复剂
- 批准号:
10181019 - 财政年份:2016
- 资助金额:
$ 33.96万 - 项目类别:
Epithelial stem/progenitor cells as repair agents in diffuse alveolar damage
上皮干/祖细胞作为弥漫性肺泡损伤的修复剂
- 批准号:
9355470 - 财政年份:2016
- 资助金额:
$ 33.96万 - 项目类别:
Epithelial stem/progenitor cells as repair agents in diffuse alveolar damage
上皮干/祖细胞作为弥漫性肺泡损伤的修复剂
- 批准号:
10418711 - 财政年份:2016
- 资助金额:
$ 33.96万 - 项目类别:
Epithelial Stem/Progenitor Cells in Repair of the Injured Lung
上皮干细胞/祖细胞修复受损肺
- 批准号:
9109038 - 财政年份:2015
- 资助金额:
$ 33.96万 - 项目类别:
Identification, Isolation, and Reprogramming Alveolar Epithelial Progenitor Cells
肺泡上皮祖细胞的鉴定、分离和重编程
- 批准号:
7676645 - 财政年份:2008
- 资助金额:
$ 33.96万 - 项目类别:
Urokinase Receptor Integrin Interactions in Lung Cancer
肺癌中尿激酶受体整合素相互作用
- 批准号:
7318124 - 财政年份:2007
- 资助金额:
$ 33.96万 - 项目类别:
相似海外基金
Modulation of T lymphocyte Activation by Ã2-Adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
RGPIN-2019-06980 - 财政年份:2022
- 资助金额:
$ 33.96万 - 项目类别:
Discovery Grants Program - Individual
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
- 批准号:
10581488 - 财政年份:2022
- 资助金额:
$ 33.96万 - 项目类别:
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574979-2022 - 财政年份:2022
- 资助金额:
$ 33.96万 - 项目类别:
University Undergraduate Student Research Awards
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
- 批准号:
10332251 - 财政年份:2022
- 资助金额:
$ 33.96万 - 项目类别:
Modulation of T lymphocyte Activation by Ã2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574984-2022 - 财政年份:2022
- 资助金额:
$ 33.96万 - 项目类别:
University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574985-2022 - 财政年份:2022
- 资助金额:
$ 33.96万 - 项目类别:
University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by Ã2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574978-2022 - 财政年份:2022
- 资助金额:
$ 33.96万 - 项目类别:
University Undergraduate Student Research Awards
Investigating the cell-based activity of a new class of cytotoxic T-lymphocyte antigen-4 (CTLA-4) small molecule inhibitors
研究一类新型细胞毒性 T 淋巴细胞抗原 4 (CTLA-4) 小分子抑制剂的细胞活性
- 批准号:
444149 - 财政年份:2021
- 资助金额:
$ 33.96万 - 项目类别:
Operating Grants
Novel pathways in T lymphocyte differentiation and function
T 淋巴细胞分化和功能的新途径
- 批准号:
RGPIN-2015-05491 - 财政年份:2021
- 资助金额:
$ 33.96万 - 项目类别:
Discovery Grants Program - Individual
Modulation of T lymphocyte Activation by ß2-Adrenergic Receptor Signalling Pathways
通过 α2-肾上腺素能受体信号通路调节 T 淋巴细胞激活
- 批准号:
RGPIN-2019-06980 - 财政年份:2021
- 资助金额:
$ 33.96万 - 项目类别:
Discovery Grants Program - Individual